The GLP is committed to full transparency. Download and review our 2019 Annual Report

CRISPR’s lengthy patent legal battle could finally end—in a tie

| | March 11, 2019

This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Like a couple of heavyweight boxers who just keep slugging it out, the University of California Berkeley (UCB) and the Broad Institute continue to pummel each other through the courts. No knockout blows yet, but in the latest ruling from the US Patent and Trademark Office, UCB may finally be ahead on points.

These two behemoths of genetic research are fighting over ownership of the breakthrough technology known as CRISPR-Cas9.

In the USA the valuable claims were granted for the Broad Institute. UCB cried foul, insisting that Feng Zhang’s demonstration that he could make gene-editing work in cells was nothing more than an obvious add-on to the work of Doudna and Charpentier and shouldn’t be given a dominant patent position.

Related article:  Bacterial gene found in CRISPR-edited cow DNA raises new regulatory hurdles for animal gene editing

The US Patent and Trademark Office has now completed its examination of a key patent application from UCB, and has signalled that it intends to accept their claims.

A tie is very rare in a boxing match. But perhaps in this contest we’re approaching the time for the two corners to get together and agree cross-licensing strategies and agreements before everyone is too punch-drunk to continue fighting effectively.

Read full, original post: The epic legal battle over CRISPR’s future could finally be over

News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend